Research programme: skin disorder therapeutics - Parion Sciences
Latest Information Update: 28 Nov 2022
At a glance
- Originator Parion Sciences
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Epithelial sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Skin-disorders in USA
- 08 Oct 2018 Parion Sciences has patent protection for sodium channel inhibitors for Skin disorders in USA
- 08 Oct 2018 Preclinical trials in Skin disorders in USA (unspecified route) (Parion Sciences pipeline, October 2018)